ATE112317T1 - Bcrf1-proteine als inhibitoren von interferon- g(g). - Google Patents

Bcrf1-proteine als inhibitoren von interferon- g(g).

Info

Publication number
ATE112317T1
ATE112317T1 AT91902258T AT91902258T ATE112317T1 AT E112317 T1 ATE112317 T1 AT E112317T1 AT 91902258 T AT91902258 T AT 91902258T AT 91902258 T AT91902258 T AT 91902258T AT E112317 T1 ATE112317 T1 AT E112317T1
Authority
AT
Austria
Prior art keywords
interferon
inhibitors
bcrf1
proteins
bcrf1 proteins
Prior art date
Application number
AT91902258T
Other languages
English (en)
Inventor
Kevin W Moore
Robert A Kastelein
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE112317T1 publication Critical patent/ATE112317T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT91902258T 1989-12-20 1990-12-18 Bcrf1-proteine als inhibitoren von interferon- g(g). ATE112317T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45393189A 1989-12-20 1989-12-20

Publications (1)

Publication Number Publication Date
ATE112317T1 true ATE112317T1 (de) 1994-10-15

Family

ID=23802631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91902258T ATE112317T1 (de) 1989-12-20 1990-12-18 Bcrf1-proteine als inhibitoren von interferon- g(g).

Country Status (27)

Country Link
US (2) US5627155A (de)
EP (1) EP0506836B1 (de)
JP (1) JP2648236B2 (de)
KR (1) KR960015199B1 (de)
CN (1) CN1057012C (de)
AT (1) ATE112317T1 (de)
AU (1) AU7899694A (de)
CA (1) CA2071907C (de)
CZ (1) CZ283049B6 (de)
DE (1) DE69013011T2 (de)
DK (1) DK0506836T3 (de)
ES (1) ES2064082T3 (de)
FI (1) FI104883B (de)
HK (1) HK185396A (de)
HU (1) HU215909B (de)
IE (1) IE72203B1 (de)
IL (1) IL96715A0 (de)
MX (1) MX9203409A (de)
MY (1) MY107449A (de)
NO (1) NO305703B1 (de)
NZ (1) NZ236512A (de)
OA (1) OA09703A (de)
PH (1) PH31669A (de)
PT (1) PT96231B (de)
SK (1) SK279830B6 (de)
WO (1) WO1991009127A1 (de)
ZA (1) ZA9010188B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
CA2070416A1 (en) * 1989-10-23 1991-04-24 Richard Ingram Polypeptide inhibitors of gamma interferon
DE69201128T2 (de) * 1991-01-16 1995-05-24 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
US6106823A (en) * 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
US6008327A (en) 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
DE69332197T2 (de) * 1992-03-13 2003-04-17 Organon Teknika B.V., Boxtel Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
ATE207120T1 (de) * 1993-07-23 2001-11-15 Hans Prof Dr Wolf Dna-sequenzen des epstein-barr virus kodierend für ein diagnostisch relevantes virus-hüllprotein,durch pcr erhaltene expressionsklone und verwendung dieses rekombinanten antigens in diagnostischen tests
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
ATE413881T1 (de) * 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
SG11201402490XA (en) 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
WO2022016509A1 (zh) * 2020-07-24 2022-01-27 阎忠扬 一种用以筛选药物的方法,以及该药物用于治疗牛皮癣的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
US5256768A (en) * 1985-12-13 1993-10-26 The Johns Hopkins University Expression of antigenic Epstein-Barr virus polypeptides in bacteria and their use in diagnostics

Also Published As

Publication number Publication date
JPH05503846A (ja) 1993-06-24
IL96715A0 (en) 1991-09-16
CA2071907C (en) 2000-08-08
AU652732B2 (en) 1994-09-08
FI922770L (fi) 1992-06-16
PH31669A (en) 1999-01-18
WO1991009127A1 (en) 1991-06-27
HK185396A (en) 1996-10-11
HU215909B (hu) 1999-03-29
PT96231B (pt) 1998-09-30
CN1057012C (zh) 2000-10-04
SK635190A3 (en) 1999-04-13
KR960015199B1 (ko) 1996-11-01
NZ236512A (en) 1997-07-27
IE904588A1 (en) 1991-07-03
DE69013011T2 (de) 1995-02-23
CZ283049B6 (cs) 1997-12-17
EP0506836B1 (de) 1994-09-28
JP2648236B2 (ja) 1997-08-27
OA09703A (en) 1993-08-30
AU7063691A (en) 1991-07-18
PT96231A (pt) 1991-09-30
NO922456D0 (no) 1992-06-19
CN1052608A (zh) 1991-07-03
ZA9010188B (en) 1991-08-28
CA2071907A1 (en) 1991-06-21
AU7899694A (en) 1995-02-09
FI922770A0 (fi) 1992-06-16
DK0506836T3 (da) 1994-11-28
DE69013011D1 (de) 1994-11-03
HU9202075D0 (en) 1992-10-28
US5736390A (en) 1998-04-07
EP0506836A1 (de) 1992-10-07
HUT65369A (en) 1994-05-02
ES2064082T3 (es) 1995-01-16
IE72203B1 (en) 1997-04-09
US5627155A (en) 1997-05-06
NO922456L (no) 1992-06-19
CZ635190A3 (en) 1997-09-17
SK279830B6 (sk) 1999-04-13
NO305703B1 (no) 1999-07-12
FI104883B (fi) 2000-04-28
MY107449A (en) 1995-12-31
MX9203409A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
RO90639B (ro) Procedeu pentru prepararea tesutului uman activator de plasminogen
FI935585A0 (fi) Pyrrolopyrimidiner
ATE328068T1 (de) Papillomavirus vakzine
ATE246248T1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE168698T1 (de) Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
MX9304070A (es) Piperidilamidas, piperidilsulfonamidas y piperidilsulfoxamidas novedosas como inhibidores de la biosintesis del colesterol.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
HUP9901161A2 (hu) Módosított aktivitású hibrid VIII. faktor
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
IL99940A0 (en) Beta-galactoside binding proteins,methods for the production thereof,and pharmaceutical compositions containing the same
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
DE50203154D1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee